Related Experiment Videos
PDCD4 functions as a suppressor for pT2a and pT2b stage gastric cancer
Peng-Tao Guo1, Dong Yang, Zhe Sun
1Department of Surgical Oncology, First Affiliated Hospital, China Medical University, Shenyang, Liaoning 110001, PR China.
Abstract:
Gastric cancer is one of the leading causes of cancer‑related mortality worldwide. Loss of programmed cell death 4 (PDCD4) expression has been detected in gastric cancer. However, the effects of PDCD4 on pT2 stage gastric cancer remain unclear. The aim of this study was to identify the relationship between PDCD4 expression and clinicopathological features of patients with pT2 stage gastric cancer. In the present study, 122 pT2 stage gastric cancer specimens were subclassified as pT2a and pT2b stage. The levels of PDCD4 mRNA and protein in gastric cancer tissues were lower compared to that in normal tissues as detected by real‑time PCR and western blot analysis, respectively. In addition, both PDCD4 mRNA and protein in pT2b stage gastric cancer were lower when compared to that in pT2a stage gastric cancer. Finally, we used immuno-histochemistry to determine the protein expression and analyzed the relationship between PDCD4 expression and the clinicopathological features of pT2 stage gastric cancer patients. Cumulative survival rate of patients with PDCD4 expression was significantly higher compared to the patients without PDCD4 expression. PDCD4 expression in gastric cancer can be employed to indicate a favorable prognosis for the disease outcome.
Insights
Programmed cell death 4 (PDCD4) expression is reduced in gastric cancer, particularly in pT2b stage. Lower PDCD4 levels correlate with poorer prognosis, while its presence indicates a favorable outcome for gastric cancer patients.
Area of Science:
- Oncology
- Molecular Biology
Background:
- Gastric cancer is a significant global health concern, contributing to high mortality rates.
- Reduced expression of programmed cell death 4 (PDCD4) has been observed in gastric cancer, but its specific role in pT2 stage remains unclear.
Purpose of the Study:
- To investigate the relationship between PDCD4 expression and clinicopathological features in patients with pT2 stage gastric cancer.
- To evaluate PDCD4's prognostic value in pT2 stage gastric cancer.
Main Methods:
- Analysis of 122 pT2 stage gastric cancer specimens, subclassified into pT2a and pT2b stages.
- Quantification of PDCD4 mRNA and protein levels using real-time PCR and Western blot.
- Assessment of PDCD4 protein expression via immunohistochemistry.
Main Results:
- PDCD4 mRNA and protein levels were significantly lower in gastric cancer tissues compared to normal tissues.
- PDCD4 mRNA and protein levels were further reduced in pT2b stage gastric cancer compared to pT2a stage.
- Patients with PDCD4 expression exhibited a significantly higher cumulative survival rate.
Conclusions:
- PDCD4 expression is diminished in pT2 stage gastric cancer, with lower levels in pT2b compared to pT2a.
- PDCD4 expression serves as a favorable prognostic biomarker for gastric cancer outcomes.
Related Concept Videos
Abnormal Proliferation
Gastritis II: Pathophysiology
Inhibition of Cdk Activity
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...